Roth Capital Comments On Sarepta Therapeutics Ahead Of 3Q14 Update
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price target, which represents a potential upside of 35% from where the stock is currently trading.
Chattopadhyay noted, “Sarepta’s 3Q update (11/06/14) is likely to focus on its ongoing dialogue with the FDA. The agency’s recent communication with Sarepta potentially reflects their frustration with Sarepta’s inability to get its pivotal study underway, in our view. Hence, we hope that the delay in dosing patients is behind us and Sarepta is also moving forward rapidly with other exon skipping drug candidates.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -11.7% and a 36.7% success rate. Chattopadhyay has a -26.5% average return when recommending SRPT, and is ranked #3301 out of 3358 analysts.